Elevance Health, Inc.
Congressional Trades
Whale Activity
- Increased610
- New149
- Held249
- Decreased549
- Closed120
- No prior filing76
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 19.5M | $7.59B | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 13.8M | $5.37B | decreased |
| STATE STREET CORP | 10.5M | $4.08B | increased |
| WELLINGTON MANAGEMENT GROUP LLP | 8.5M | $3.31B | decreased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6.2M | $2.41B | decreased |
| Sanders Capital, LLC | 5.8M | $2.27B | increased |
| GEODE CAPITAL MANAGEMENT, LLC | 5.2M | $2.02B | increased |
| Invesco Ltd. | 5.1M | $1.97B | increased |
| HARRIS ASSOCIATES L P | 4.8M | $1.86B | decreased |
| First Eagle Investment Management, LLC | 4.2M | $1.63B | increased |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.9M | $1.51B | decreased |
| Artisan Partners Limited Partnership | 3.8M | $1.46B | decreased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| PERU RAMIRO GDirector · Director | Purchase | +1,000 | $383.86 | $384K | Nov 19, 2026 | Form 4 ↗ |
| LAVU RATNAKAREVP & Chief Digital Info Ofr | Sale | −1,300 | $440.00 | $572K | Nov 5, 2026 | Form 4 ↗ |
| Kaye MarkEVP & CFO | Sale | −827 | $446.05 | $369K | Oct 22, 2026 | Form 4 ↗ |
| Kaye MarkEVP & CFO | Sale | −560 | $437.07 | $245K | Oct 22, 2026 | Form 4 ↗ |
| Kaye MarkEVP & CFO | Sale | −480 | $442.61 | $212K | Oct 22, 2026 | Form 4 ↗ |
| Kaye MarkEVP & CFO | Sale | −440 | $443.81 | $195K | Oct 22, 2026 | Form 4 ↗ |
| Kaye MarkEVP & CFO | Sale | −400 | $434.00 | $174K | Oct 22, 2026 | Form 4 ↗ |
| Kaye MarkEVP & CFO | Sale | −321 | $435.25 | $140K | Oct 22, 2026 | Form 4 ↗ |
| Kaye MarkEVP & CFO | Sale | −273 | $447.19 | $122K | Oct 22, 2026 | Form 4 ↗ |
| Kaye MarkEVP & CFO | Sale | −240 | $438.22 | $105K | Oct 22, 2026 | Form 4 ↗ |
| Kaye MarkEVP & CFO | Sale | −2,343 | $441.34 | $1.0M | Oct 22, 2026 | Form 4 ↗ |
| Kaye MarkEVP & CFO | Sale | −1,720 | $440.44 | $758K | Oct 22, 2026 | Form 4 ↗ |
| Kaye MarkEVP & CFO | Sale | −1,660 | $436.20 | $724K | Oct 22, 2026 | Form 4 ↗ |
| Kaye MarkEVP & CFO | Sale | −160 | $444.85 | $71K | Oct 22, 2026 | Form 4 ↗ |
| Kaye MarkEVP & CFO | Sale | −1,160 | $439.25 | $510K | Oct 22, 2026 | Form 4 ↗ |
| Wessling Erin MEVP & Chief Legal Officer | Tax withholding | −255 | $414.78 | $106K | Sep 3, 2026 | Form 4 ↗ |
| Wessling Erin MEVP & Chief Legal Officer | Tax withholding | −94 | $405.84 | $38K | Sep 2, 2026 | Form 4 ↗ |
| Craig Ryan REVP & Chief HR Officer | Tax withholding | −144 | $405.84 | $58K | Sep 2, 2026 | Form 4 ↗ |
| BOUDREAUX GAILPresident and CEO · Director | Purchase | +2,045 | $368.25 | $753K | Jul 17, 2026 | Form 4 ↗ |
| BOUDREAUX GAILPresident and CEO · Director | Purchase | +680 | $366.41 | $249K | Jul 17, 2026 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 6.6M | $2.56B | 0.11% | Jun 30, 2026 |
| VANGUARD 500 INDEX FUND VANGUARD INDEX FUNDS | 5.4M | $2.08B | 0.12% | Jun 30, 2026 |
| iShares Core S&P 500 ETF iShares Trust | 3.0M | $1.16B | 0.13% | Jun 30, 2026 |
| VANGUARD WINDSOR II FUND VANGUARD WINDSOR FUNDS | 3.0M | $1.14B | 1.71% | Jul 31, 2026 |
| Fidelity 500 Index Fund Fidelity Concord Street Trust | 2.8M | $1.11B | 0.13% | Aug 31, 2026 |
| First Eagle Global Fund First Eagle Funds | 2.8M | $1.07B | 1.41% | Jul 31, 2026 |
| State Street(R) SPDR(R) S&P 500(R) ETF Trust | 2.6M | $1.02B | 0.13% | Jun 30, 2026 |
| VANGUARD EQUITY INCOME FUND VANGUARD FENWAY FUNDS | 2.0M | $791.3M | 1.21% | Jun 30, 2026 |
| VANGUARD VALUE INDEX FUND VANGUARD INDEX FUNDS | 2.0M | $782.5M | 0.31% | Jun 30, 2026 |
| VANGUARD HEALTH CARE FUND VANGUARD SPECIALIZED FUNDS | 1.9M | $698.4M | 1.83% | Jul 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list ELV's shares (CUSIP 036752103), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
No 13D/13G beneficial-ownership filings on record.
Corporate Lobbying
- CAPITOL HILL CONSULTING GROUPELEVANCE HEALTH, INC · 2026 Q3 · MMM, HCR$60K
Filing ↗ - ELEVANCE HEALTH, INC.ELEVANCE HEALTH, INC. · 2026 Q3 · HCR, MMM, INS, PHA$1.4M
Filing ↗ - TARPLIN, DOWNS & YOUNG, LLCELEVANCE HEALTH, INC (F.K.A. ANTHEM, INC. & WELLPOINT, INC.) · 2026 Q3 · BUD, HCR, VET, TAX$80K
Filing ↗ - ALB SOLUTIONSELEVANCE HEALTH, INC. · 2026 Q3 · HCR$60K
Filing ↗ - MEHLMAN CONSULTING, INC.ELEVANCE HEALTH, INC. · 2026 Q3 · HCR, MMM, PHA, TAX$90K
Filing ↗
Government Contracts
No federal contract awards found for Elevance Health, Inc..
U.S. Patents
No USPTO patent applications found for Elevance Health, Inc..
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $199.13B | $177.01B | $171.34B | $156.59B | $138.64B |
| Operating income | $7.20B | $7.86B | $8.50B | $8.28B | $7.56B |
| Net income | $5.66B | $5.98B | $5.99B | $5.89B | $6.16B |
| Diluted EPS | $25.21 | $25.68 | $25.22 | $24.28 | $24.95 |
| Operating cash flow | $4.29B | $5.81B | $8.06B | $8.40B | $8.36B |
| Cash and equivalents | $9.49B | $8.29B | $6.53B | $7.39B | $4.88B |
| Total assets | $121.49B | $116.89B | $108.93B | $102.75B | $97.46B |
| Total liabilities | $77.47B | $75.46B | $69.52B | $66.42B | $61.33B |
| Shareholders' equity | $43.88B | $41.31B | $39.31B | $36.24B | $36.06B |
As Elevance Health, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 6, 2026 ↗
Stock Splits
- 2-for-1Stock splitJun 1, 2005
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
- 8-K · Items 7.01Reg FD disclosureNov 10, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsOct 21, 2026
EDGAR ↗ - 8-K · Items 7.01Reg FD disclosureSep 10, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsJul 15, 2026
EDGAR ↗ - 8-K · Items 7.01Reg FD disclosureJun 10, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteMay 13, 2026
EDGAR ↗







